EMPRISE-Study
EMPRISE-Study
Search
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
10 things you should know about rabies
10 things you should know about rabies
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
World Veterinary Day aspects veterinary profession
• World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction